Other languages Nxera Pharma Co., Ltd.

Equities

4565

JP3431300007

Delayed Japan Exchange Other stock markets 12:49:24 2024-05-02 am EDT			5-day change	1st Jan Change
1,516 ^JPY	+1.47%		+2.57%	+6.83%

Apr. 18	Nxera Pharma Initiates Restricted Stock Unit Plans, Starting with Shares Worth 164 Million Yen in Total in May	MT
Apr. 17	Nxera Pharma's Neuro Drug NBI-1117568 Passed Preclinical Toxicity Test	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Nxera Pharma Notes Successful Development Progress of Partnered Schizophrenia Candidate NBI-1117568	Apr. 16
Nxera Pharma Announces Exclusive Supply and Distribution Agreement with Handok for Pivlaz in South Korea	Apr. 14
Nxera Pharma Appoints Patrick Branch as Head of Business Development for Japan and APAC	Apr. 03
Sosei Shareholders Greenlight Name Change, Top Management Appointments	Mar. 28
Sosei Group Corporation Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease	Mar. 20
Sosei Group Corporation Doses First Subject in a Phase 1 Trial Evaluating its Novel EP4 Receptor Agonist, HTL0033744 (HTL'744) for the Treatment of Inflammatory Bowel Disease	Mar. 20
Idorsia perçoit 350 millions de dollars pour les sélatogreé et cénérimod	Mar. 18
Sosei Group, Boehringer Ingelheim Enter Into License Deal for Schizophrenia Symptoms	Mar. 12
Boehringer Ingelheim and Sosei Heptares Join Forces to Develop First-In-Class Treatments Targeting All Symptoms of Schizophrenia	Mar. 11
Boehringer Ingelheim and Sosei Group Corporation Enter Exclusive Option-To- License Agreement	Mar. 11
Japanese Shares Close Lower But Hit Fresh 52-Week High on US Rate Cut Assurance	Mar. 07
Sosei Group to Get $2.5 Million Milestone Payment from Formosa Pharmaceuticals	Mar. 07
Sosei Group Corporation to Receive $2.5 Million Payment from Formosa Pharmaceuticals	Mar. 06
Idorsia cède encore des programmes en échange de financements	Feb. 28
Drugmakers deepen efforts to tap into booming market for obesity drugs	Feb. 27
Sosei Group Corporation Appoints Toshihiro Maeda as Chief Operating Officer	Jan. 05
Sosei Group Corporation Announces Marketing Approval for PIVLAZ (Clazosentan Sodium) 150 Mg in South Korea	Dec. 07
Sosei Partner to Conduct Early Stage Trials of Neurological Disease Drug Candidates	Dec. 06
Roche enters obesity drugs race with $2.7 bln Carmot deal	Dec. 04
Roche enters obesity drugs race with $2.7 bln Carmot deal	Dec. 04

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Nxera Pharma Co., Ltd.

Equities

4565

JP3431300007

Other languages

Filters